 | Kickstart your business’ marketing with FedEx Office! Save big on posters, postcards and brochures, with up to 40% off on select print products. Go to FedEx Office to take advantage of the Look Good On Paper Print Sale to get discounts on all your business printing needs. |
  | Health Care & Policy |  |  | | - Stem cells help wean transplant patients off anti-rejection drugs
Eight of 12 patients who received kidney transplants have been off of immune-suppressing drugs for at least a year after undergoing a technique that involves the infusion of hematopoietic progenitor cells, according to a study published in the New England Journal of Medicine. Scientists at the Stanford University School of Medicine developed the method, which also includes radiation therapy and introduction of antibodies into patients. They plan to further test the technique by recruiting patients whose immune systems are less compatible to transplanted organs. HealthDay News (10/5)       - Data from failed clinical trials should be reported, researchers say
Data from discontinued drug trials should be reported so other researchers can glean information for use in their studies and to provide the public with information on side effects, according to a recent paper in Science Translational Medicine. "Even negative studies provide important scientific information, and the patients who participated in the trials expect that the information derived from their participation will benefit mankind," said co-author Michael Rogawski, who chairs the Department of Neurology at the University of California, Davis. The FDA should require drugmakers to report trial data at ClinicalTrials.gov even for drugs that are abandoned, he said. Pharmalot.com (10/5) - Experts ID diabetes gene in tested mice
A study of mice revealed that a certain gene controls a protein called tomosyn-2, which appeared to inhibit insulin secretion in the pancreas. Experts compared diabetes-resistant and diabetes-susceptible mice and noted a single amino acid difference that thwarted tomosyn-2 in resistant mice, which enabled them to produce sufficient amounts of insulin. "It's too early for us to know how relevant this gene will be to human diabetes, but the concept of negative regulation is one of the most interesting things to come out of this study and that very likely applies to humans," study lead author Alan Attie said. Google/The Press Association (U.K.) (10/6)  | Fly a lot? Earn 3X rewards points on airline purchases with The New Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
• Plus, 50K bonus points when you spend $10K your first 5 months
LEARN MORE AND APPLY |
  - Immune Design secures additional $11 million in venture capital
Immune Design said in a regulatory filing that it obtained an additional $11 million in venture capital, bringing its total raised in its Series B financing round to up to $23.4 million. The company is working on adjuvants, designed to improve the efficacy of vaccines, and a delivery technology that can stimulate an immune defense against diseases, such as influenza. Xconomy/Seattle (10/5)  | FREE TRIAL – Thomson Reuters Cortellis™ Pipeline Intelligence
Discover new opportunities in drug development and licensing faster. Cortellis gives you an innovative way of finding and acting on drug pipelines, deals, patents, companies, breaking industry news, and conference coverage in one source, intuitively presented.
Click here to see if you qualify for a free trial! |
| Industrial & Environmental | |  | | |  |  | LET’S GO DESIGN: Episode #5
In this episode of SolidWorks’ interactive web series, Jeremy moves closer to the final design of our Hot Rod Baby Buggy and also hot-wires the golf cart motor to show how the aluminum tracks perform flawlessly. Watch at LetsGoDesign.tv. |
 | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.
| SmartQuote | | | |  | Any activity becomes creative when the doer cares about doing it right, or better."
--John Updike,
American writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, October 06, 2011
- Wednesday, October 05, 2011
- Tuesday, October 04, 2011
- Monday, October 03, 2011
- Friday, September 30, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment